• Long-Acting HIV Regimen Maintains High Viral Suppression in Real-World Study

    Long-Acting HIV Regimen Maintains High Viral Suppression in Real-World Study
    Originally published by our sister publication Infectious Disease Special EditionBy Ethan CoveyLong-acting cabotegravir plus rilpivirine (CAB+RPV LA; Cabenuva, ViiV Healthcare) maintained viral suppression in the vast majority of people with HIV who switched from oral antiretroviral therapy (ART), with confirmed virologic failure occurring in just 1%, according to five-year findings from the OPERA cohort presented at IDWeek 2026, in Washington, D.C. (oral abstract 73).figure { display:inline-blo
  • 8 Steps to Strengthen Your Hazardous Drug Program

    8 Steps to Strengthen Your Hazardous Drug Program
    By Karen BlumThe 2024 update to the National Institute for Occupational Safety and Health (NIOSH) List of Hazardous Drugs in Healthcare Settings answered some long-standing questions, but it did not eliminate hospitals’ responsibility for identifying and safely handling hazardous medications.The revised list excludes entire categories of products, including biologics approved through the FDA’s Center for Biologics Evaluation and Research, and does not include drugs approved since 2015. As a

Follow @newsl_pharmacy on Twitter!